KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Gains from Investment Securities: 2009-2024

Historic Gains from Investment Securities for Emergent BioSolutions (EBS) over the last 16 years, with Dec 2024 value amounting to -$6.5 million.

  • Emergent BioSolutions' Gains from Investment Securities was N/A to -$400,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year change of. This contributed to the annual value of -$6.5 million for FY2024, which is 180.25% down from last year.
  • According to the latest figures from FY2024, Emergent BioSolutions' Gains from Investment Securities is -$6.5 million, which was down 180.25% from $8.1 million recorded in FY2023.
  • In the past 5 years, Emergent BioSolutions' Gains from Investment Securities ranged from a high of $31.7 million in FY2020 and a low of -$6.5 million during FY2024.
  • Its 3-year average for Gains from Investment Securities is $2.5 million, with a median of $5.9 million in 2022.
  • Per our database at Business Quant, Emergent BioSolutions' Gains from Investment Securities surged by 37.29% in 2023 and then slumped by 180.25% in 2024.
  • Over the past 5 years, Emergent BioSolutions' Gains from Investment Securities (Yearly) stood at $31.7 million in 2020, then tumbled by 56.47% to $13.8 million in 2021, then plummeted by 57.25% to $5.9 million in 2022, then spiked by 37.29% to $8.1 million in 2023, then slumped by 180.25% to -$6.5 million in 2024.